当前位置: 首页 > 期刊 > 《现代医药卫生》 > 2007年第16期
编号:11486065
多药耐药机制的探究(3)
http://www.100md.com 2007年8月15日 《现代医药卫生》 2007年第16期
     [4] Kat hleen Christine l.Expenience Wht hv PICC at a university medicql center [J].J Iniraven Nurs,2006,20:141.

    [5] Lopes EC,Garcia M,Benavides F,et al.Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lym-phoid leukemia cell lines independently of their MDR phenotype[J].Leuk Res,2003,27(5):4132423.

    [6] Kusama T,Mukai M,Ayaki M,et al.Inhibition of lysophosphatidic aci-d2induced RhoA activation and tumor cell invasion by 32hydroxy232m-ethylglutaryl2coenzyme A reductase inhibitors[J].Int J Oncol,2003,23(4):117321178.

    [7] Wang DS,Dou KF,Li KZ,et al.Enhancement of migration and invasion of hepatoma cells via a Rho GTPase signaling pathway[J].World J Gast roenterol,2004,10 (2):2992302.

    [8] 郭天剑,袁亚维,孙爱民,等.对MDR肿瘤细胞KBV200的PKC-ct亚型cDNA克隆序列的研究[J].肿瘤研究与临床,2002,14(3):294.

    [9] Coon M,Ball A,Pound J,et al.Inhibition of lysophosphatidic acid acylt ransferasebeta disrupt s proliferative and survival signals in normal cells and induces apoptosis of tumor cells[J].Mol Cancer Ther,2003,2(10):1067278.

    收稿日期:2007-04-11 修回日期:2007-05-15

    [ 上 页 ], 百拇医药(赵健竹 赵文嫣)
上一页1 2 3